Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia
Open Access
- 7 February 2021
- journal article
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (4) , 329-336
Abstract
Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumoniaKeywords
This publication has 6 references indexed in Scilit:
- Cost-Effectiveness Of Culture-Based Versus Empirical Antibiotic Treatment For Hospitalized Adults With Community-Acquired Pneumonia In Indonesia: A Real-World Patient-Database StudyClinicoEconomics and Outcomes Research, 2019
- Antibiotics and community-acquired lower respiratory tract infections. To whom? Which one?Clinical Microbiology and Antimicrobial Chemotherapy, 2019
- Pneumonia as an actual medical problem of the 21th centuryPULMONOLOGIYA, 2015
- Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parametersSwiss Medical Weekly, 2013
- Clinical and economic burden of community-acquired pneumonia among adults in EuropeThorax, 2010
- Empiric Therapy of Community-Acquired PneumoniaChest, 2004